Form 4: BridgeBio Pharma Director Frank McCormick Disposes of 7,400 Shares

Director Frank McCormick disposed of 7,400 shares of BridgeBio Pharma stock on December 26, 2024, reducing his direct holdings.

Summary

• Frank McCormick, a director at BridgeBio Pharma, disposed of 7,400 shares of common stock on December 26, 2024.
• The transaction was a disposal, not a sale, and the price was $0.
• Following the transaction, McCormick directly owns 464,976 shares of BridgeBio Pharma.
• McCormick also indirectly owns 627,689 shares through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a stock transaction by a director, with no inherent positive or negative sentiment.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company director, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Director stock transactions are a common occurrence in publicly traded companies, including those in the pharmaceutical sector.
• These transactions are typically disclosed via SEC Form 4 filings, which are standard practice.
• The size of this transaction is not unusual for a director's holdings.

Stakeholder Impact

• The transaction may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the stock price.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Frank McCormick, Director, Stock Disposal, Beneficial Ownership, SEC Form 4